Hideyuki Waki

Taisho Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following divisions: Self-Medication, Prescription Pharmaceutical and Overseas Development. The Self-Medication division deals with the research, development, and production of over-the-counter (OTC) drugs, medical supplies, food for specific health use, and hygiene products. The Prescription Pharmaceutical division handles research and development of new drugs in the fields of central nervous system diseases, metabolic diseases, infectious diseases, and inflammatory diseases. The Overseas Development division markets energy drinks and OTC pharmaceuticals overseas. The company was founded on October 12, 1912 and is headquartered in Tokyo, Japan.

Biofermin Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products, quasi-drugs, veterinary drugs, agrichemicals, cosmetics, medical equipment, foods, beverages, food additives, feeds, feed additives and other chemicals. Its products include pharmaceutical items such as New Biofermin S, Biofermin Antidiarrheal, Biofermin, Stomachic Tablets, Biofermin VC, Biofermin Laxatives, Biofermin R, etc. It also provides various clinical test services. The company was founded on February 12, 1917 and is headquartered in Kobe, Japan.